Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?

Core Viewpoint - Arcutis Biotherapeutics, Inc. (ARQT) shows significant potential for upside, with a mean price target of $16.50 indicating a 54.8% increase from the current price of $10.66, despite recent gains of 14.6% over the past four weeks [1] Price Targets and Analyst Consensus - The mean price target consists of six short-term estimates with a standard deviation of $6.44, suggesting variability in analyst opinions; the lowest estimate is $8 (25% decline), while the highest is $26 (143.9% increase) [1] - Analysts' price targets are often viewed with skepticism due to potential biases and inflated estimates driven by business relationships [3][4] Earnings Estimates and Market Sentiment - Analysts are optimistic about ARQT's earnings prospects, as indicated by a 6% increase in the Zacks Consensus Estimate for the current year, with two estimates revised upward and no negative revisions [5] - The company holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for near-term upside [5]